AlphAIAlphAI — Financial news for AI agents
investing.com$GKOS

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

Original reporting
investing.com
Published Oct 29, 2026, 2:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GKOS
Bullish
high confidence
Mentioned
$GKOS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

The earnings beat and guidance raise suggest a catalyst for short‑term price appreciation, especially as the stock is already near its 52‑week high.

02

Market read

Earnings beat and upgraded targets provide a fresh catalyst for GKOS, likely driving short‑term buying interest.

03

What to watch

Potential regulatory or reimbursement hurdles for the new Epioxa product could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Glaukos (GKOS) reported Q3 results that beat estimates and raised its FY2026 revenue outlook, prompting several analysts to increase price targets.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Piper Sandler raised its price target to $240 on Glaukos after reporting Q3 revenue of $211M and raising FY2026 guidance to $775‑$785M.

Expected impact

likely upward pressure as the market prices in higher guidance and raised targets

Evidence & confidence

The combination of a 58% revenue beat, first positive adjusted earnings, and multiple analysts lifting targets provides fresh, material information that can move the share price.

Market effects

Sector

Strong performance may lift sentiment in the ophthalmology and broader biotech sector.

Regional

Positive for US biotech stocks trading on NYSE.

Global

Limited to investors focused on US‑listed biotech firms.

Counterpoint

What could challenge this read

Some investors may view the rapid target hikes as overoptimistic given the company's small size and execution risk.

Key entities

  • analyst
    Piper Sandler

    Raised price target to $240 and maintained Overweight rating.

  • analyst
    Needham

    Raised price target to $251.

  • analyst
    Mizuho

    Raised price target to $225.

  • analyst
    Truist Securities

    Raised price target to $255.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com